Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.
To assess the potential for cross-protection among genital human papillomavirus (HPV) types in virus-like particle (VLP)-based vaccinations, inhibition of HPV VLP-mediated hemagglutination by rabbit antisera raised against HPV type 6b (HPV-6b), HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, and HPV-45 was analyzed. Only highly homologous types (HPV-6b and HPV-11, and HPV-18 and HPV-45) exhibited detectable serological cross-reaction for the class of antibodies that inhibit virion-to-cell surface binding. However, analysis of neutralizing monoclonal antibodies to several animal and human papillomaviruses indicated that over half of these antibodies do not prevent cell surface binding, but these latter antibodies do not appear to be more cross-reactive in enzyme-linked immunosorbent assays than those that mediate inhibition of hemagglutination. The data strongly suggest that while there may be limited cross-protection between highly (>85% L1 amino acid identity) homologous types, protection by HPV VLP-based vaccines will be predominantly type specific.
Roden
R B
RB
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA.
Hubbert
N L
NL
Kirnbauer
R
R
Christensen
N D
ND
Lowy
D R
DR
Schiller
J T
JT
D000818:Animals; D000911:Antibodies, Monoclonal; D002584:Cervix Uteri / Q000821:virology; D004912:Erythrocytes; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007106:Immune Sera; D051379:Mice; D009500:Neutralization Tests; D009856:Oncogene Proteins, Viral / Q000276:immunology* / Q000302:isolation & purification; D027383:Papillomaviridae / Q000145:classification* / Q000276:immunology / Q000502:physiology*; D011817:Rabbits; D011991:Receptors, Virus / Q000502:physiology; D014771:Virion / Q000502:physiology
D000911:Antibodies, Monoclonal; D007106:Immune Sera; D009856:Oncogene Proteins, Viral; D011991:Receptors, Virus